Recombinant Staphylococcus epidermidis for Filaggrin Secretion in Ichthyosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ichthyosis vulgaris, a chronic scaly skin disease, are inadequate in addressing the underlying pathophysiology and often lead to reduced quality of life due to their limitations in effectively managing skin barrier defects and associated conditions like atopic dermatitis.
Innovation Solution
A genetically engineered recombinant strain of Staphylococcus epidermidis is used to secrete human filaggrin, providing a stable and long-term delivery of this structural protein to enhance skin hydration and barrier function, thereby addressing the disease's pathophysiology and improving skin health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current topical treatments (water evaporation suppressants and moisturizers) are used for ichthyosis vulgaris, then skin hydration is improved, but the underlying pathophysiology (filaggrin deficiency and skin barrier defects) is not effectively addressed
Solution Approach 1:
The patent uses a recombinant microorganism (Staphylococcus epidermidis) as an intermediary delivery system to transport and secrete filaggrin protein directly at the skin site. This mediator approach allows the therapeutic protein to reach the target location effectively, addressing the underlying filaggrin deficiency while maintaining improved skin hydration from topical application.
Solution Approach 2:
The recombinant microorganism is engineered to autonomously produce and secrete human filaggrin protein when applied to the skin. The microorganism serves itself by using its cellular machinery to express the therapeutic protein, eliminating the need for external production and delivery systems. This self-service capability enables continuous local production of filaggrin to address the pathophysiology.
2Productivity
If topical retinoids are used to slow skin cell production, then skin cell proliferation is reduced, but long-term use is not ideal due to potential side effects and limitations
Solution Approach 1:
The patent changes the therapeutic parameter from using retinoids (Vitamin A derivatives) to using recombinant filaggrin protein secretion. This parameter change shifts the mechanism of action from modulating skin cell production rates to directly replenishing the deficient structural protein, thereby controlling skin cell production issues without the harmful side effects associated with long-term retinoid use.
3Duration of action of moving object
If engineered probiotics are used to deliver therapeutic proteins in situ, then continuous and stable delivery is achieved, but the complexity of genetic engineering and microorganism cultivation increases
Solution Approach 1:
The recombinant microorganism autonomously produces and secretes filaggrin protein using its own cellular machinery once applied to the skin. This self-service capability enables continuous local production without requiring external delivery infrastructure or complex control systems, thereby achieving durable delivery while managing system complexity through biological self-sufficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach offers a non-steroidal, effective treatment for ichthyosis vulgaris and atopic dermatitis by stabilizing skin colonization and secreting filaggrin, improving skin hydration and barrier function, with potential for low-frequency application and improved pharmacokinetics.
Implementation Method 1
A genetically engineered recombinant strain of Staphylococcus epidermidis is used to secrete human filaggrin, providing a stable and long-term delivery of this structural protein to enhance skin hydration and barrier function
Data Source
AI summary
The present invention provides isolated plasmids, recombinant microorganisms, kits, and methods for the treatment of inflammatory skin disease.